Review Article
GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes
Pickart et al., 2018
Copper Peptide GHK
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide found in human plasma, saliva, and urine with a high affinity for copper ions. Widely used in dermatology, it has demonstrated the ability to stimulate collagen and elastin synthesis, promote wound healing, activate antioxidant enzymes, and reduce inflammatory skin damage. Commercially available OTC in cosmetic serums, creams, and injectable formulations.
Overall check-ins
Trackers & reports
Overview
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide found in human plasma, saliva, and urine with a high affinity for copper ions. Widely used in dermatology, it has demonstrated the ability to stimulate collagen and elastin synthesis, promote wound healing, activate antioxidant enzymes, and reduce inflammatory skin damage. Commercially available OTC in cosmetic serums, creams, and injectable formulations.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 45 repeat reporters
Research
Review Article
Pickart et al., 2018
PubMed
Pickart, 2008
PubMed
Pickart et al., 2014
ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Pickart et al., 2015
PubMed
Yang et al., 2022
Tools
More ways to learn about GHK-Cu from observational PeptIQ data.
Related peptides
Help
This page summarizes 120 anonymized self-reports from PeptIQ users who track GHK-Cu, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. GHK-Cu is listed as OTC Cosmetic. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests GHK-Cu may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceGHK-Cu is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified GHK-Cu as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of GHK-Cu have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on GHK-Cu, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source